NCT02691728View on ClinicalTrials.gov

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2017

Conditions
Chronic Hepatitis C
Interventions
DRUG

LDV/SOF FDC

Trial Locations (1)

90036

Peter J. Ruane, MD, Inc., Los Angeles

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Peter J. Ruane, M.D., Inc.

OTHER

NCT02691728 - Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease | Biotech Hunter | Biotech Hunter